See more : Aspen Group (APZ.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Olema Pharmaceuticals, Inc. (OLMA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Olema Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chinasoft International Limited (0354.HK) Income Statement Analysis – Financial Results
- Dhanlaxmi Fabrics Limited (DHANFAB.BO) Income Statement Analysis – Financial Results
- Inet Leasehold Real Estate Investment Trust – Inetreit (INETREIT.BK) Income Statement Analysis – Financial Results
- Helius Medical Technologies, Inc. (HSDT) Income Statement Analysis – Financial Results
- Unisys Corporation (USY1.DE) Income Statement Analysis – Financial Results
Olema Pharmaceuticals, Inc. (OLMA)
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| Gross Profit | -377.00K | -1.66M | -1.66M | -11.00K | -9.03K | -8.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.14M | 82.27M | 51.10M | 13.70M | 3.92M | 1.69M |
| General & Administrative | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 24.71M | 20.39M | 7.82M | 403.00K | 386.00K |
| Other Expenses | 0.00 | -27.00K | -47.00K | 0.00 | 0.00 | -31.00K |
| Operating Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Cost & Expenses | 104.96M | 106.99M | 71.49M | 21.53M | 4.32M | 2.08M |
| Interest Income | 8.32M | 2.23M | 442.00K | 60.00K | 7.00K | 4.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 653.00K | 0.00 | 28.00K |
| Depreciation & Amortization | 377.00K | 1.66M | 1.66M | 11.00K | 9.03K | 8.24K |
| EBITDA | -104.58M | -103.13M | -69.43M | -21.52M | -4.31M | -2.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -104.96M | -106.99M | -71.49M | -21.53M | -4.32M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.31M | 2.20M | 395.00K | -593.00K | 7.00K | -118.00K |
| Income Before Tax | -96.66M | -104.79M | -71.10M | -22.12M | -4.32M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.20M | -210.00K | 642.00K | -155.86K | -90.00K |
| Net Income | -96.66M | -102.59M | -70.89M | -22.76M | -4.32M | -2.20M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| EPS Diluted | -2.14 | -2.56 | -1.79 | -0.58 | -0.11 | -0.16 |
| Weighted Avg Shares Out | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
| Weighted Avg Shares Out (Dil) | 45.25M | 40.00M | 39.52M | 39.31M | 40.17M | 14.10M |
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the second...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
Olema Pharmaceuticals (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, July 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Forget GameStop, this stock is a perfect short-squeeze candidate
With GameStop (NYSE: GME) being a hot topic right now, with the renewed trading activity from Roaring Kitty, it is easy for traders to overlook other potential short squeeze targets that are experiencing sustainable gains, particularly in the recent sessions.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted...
Olema Oncology to Participate in Upcoming Investor Conferences in June
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will...
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced interim results from an...
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today reported financial results for the first quarter...
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024 Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024
Source: https://incomestatements.info
Category: Stock Reports